Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

NCT01374516 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

20869

Enrollment

INDUSTRY

Sponsor class

Conditions

Dengue Fever
Dengue Hemorrhagic Fever
Dengue

Interventions

BIOLOGICAL: Live, attenuated, dengue serotype 1, 2, 3, 4 virus
BIOLOGICAL: Placebo: (NaCl) 0.9% solution

Sponsor

Sanofi Pasteur, a Sanofi Company